# Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

> **NCT00349752** · PHASE3 · TERMINATED · sponsor: **UCB Pharma** · enrollment: 174 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** certolizumab pegol 400 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00349752
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 174 (ACTUAL)
- **Why stopped:** Recruitment was stopped early due to slow enrolment of this population. With no safety concerns, the study continued normally for subjects already recruited
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349752, "Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00349752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*